Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. car art

CAR ART SIGNED

Chimeric Antigen Receptor to generate Alloantigen-specific Regulatory T cells and promote allograft tolerance

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CAR ART project word cloud

Explore the words cloud of the CAR ART project. It provides you a very rough idea of what is the project "CAR ART" about.

data    global    treg    clinical    return    survival    relies    humoral    organ    terminal    pharmacologie    performed    tolerance    adoptive    alloantigen    supporting    institut    chimeric    specificity    enhanced    applicable    experimental    sufficient    clinically    graft    destructive    donor    et    transfer    limited    limitation    culaire    translation    transplant    eacute    indicated    cellular    few    immunosuppressive    morbidity    tregs    antigen    generate    vivo    outgoing    models    drugs    hindered    child    treatment    immunologists    strategies    human    infections    family    immune    ambition    prevention    position    alloimmune    allograft    lack    fellowship    receptor    preclinical    trial    action    group    lab    canada    therapy    de    redirect    overcome    cd4foxp3    regulatory    researcher    mol    transplantation    ing    grail    life    cancers    levings    alloantigens    france    indefinite    cells    rejection    pr    valbonne    recipient    markedly    car    clinic    kidney    cellulaire    potent    team    risk    ex    potency    glaichenhaus    induction    successfully    toward    vancouver    expanded    tenured   

Project "CAR ART" data sheet

The following table provides information about the project.

Coordinator		 CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 

Organization address
address: RUE MICHEL ANGE 3
city: PARIS
postcode: 75794
website: www.cnrs.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Total cost 171˙349 €
 EC max contribution 171˙349 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) coordinator 171˙349.00
2    UNIVERSITY OF BRITISH COLUMBIA CA (VANCOUVER) partner 0.00

Map

 Project objective

Organ transplantation is the best life-supporting treatment for terminal organ failure. Graft survival is however limited by rejection, a destructive process resulting from the response of recipient’s immune system against donor specific alloantigens. Prevention of rejection currently relies on immunosuppressive drugs that lack antigen specificity and therefore increase the risk for infections and cancers. Induction of donor-specific tolerance would provide indefinite graft survival without morbidity and therefore represents the Grail of transplant immunologists. Tolerance has been obtained in experimental models with adoptive transfer of ex vivo-expanded CD4FOXP3 regulatory T cells (Treg). Preclinical studies have indicated that the potency and specificity of Treg therapy could be markedly enhanced by the use of Treg specific for donor alloantigens. Translation of this approach in the clinic has been hindered by the lack of clinically applicable strategies to generate sufficient numbers of potent donor-specific Tregs. To overcome this limitation, Pr Levings’ group (Child and Family Research Institute, Vancouver, Canada) has just recently successfully used chimeric antigen receptor (CAR) technology to redirect the specificity of human Treg toward a transplant-relevant antigen. The objective of the 2-year action is to assess the impact of alloantigen-specific CAR Treg on cellular and humoral alloimmune responses and their ability to promote allograft tolerance. The outgoing phase of the global fellowship will be performed in Pr Levings’ lab, and the return phase in Pr Glaichenhaus’ team (Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France) where the researcher will get in few years a tenured position. The main ambition of the program is to provide key data for the development of a clinical trial with CAR Tregs in kidney transplantation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAR ART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAR ART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NSTree (2020)

Understanding substrate delivery for cell wall biosynthesis in plants

Read More  

MemoryAggregates (2020)

Mechanism of Whi3 Aggregation and its Age-dependent Malfunction

Read More  

CREDit (2020)

Chronological REference Datasets and Sites (CREDit) towards improved accuracy and precision in luminescence-based chronologies

Read More